Caris CDx Partnerships

Future proof with a platform built to last.

Complete DNA and RNA gene coverage uncovers novel and complex biomarkers of today and tomorrow

Co-partnership guides optimal approach of development and validation of novel CDx programs

Regulatory and commercial reach can seamlessly bridge clinical investigations to global launch

The Optimal Approach to Develop and Validate Novel CDx Biomarkers


Maximize Insights

  • Whole exome (WES), whole transcriptome (WTS)
  • All variant/alteration classes
  • Tissue enrichment
  • Tissue agnostic CDx and tumor profiling claims support use in any solid tumor indications

De-Risk Development

  • IUO materials to support analytical validation
  • Validation experience (CLIA, NY state, IDE)
  • Strong global clinical and regulatory experience

Accelerate Programs

  • MI Trials: patient identification and enrollment
  • CE mark for IVD markets
  • Established routine clinical testing

Support Global Success with Established Regulatory and Commercial Reach

  • MI Insights program provides biomarker based alerts for therapeutic commercial success
  • Caris data to support expanding use of new therapies in real world populations
  • Ability to leverage extensive salesforce and medical support for go-to market strategies
  • Strong track-record of working with payers to gain access and reimbursement

Contact Us

"*" indicates required fields

Preferred contact method*
Best time to contact